These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23967714)

  • 41. Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine.
    Aurilio C; Pace MC; Passavanti MB; Paladini A; Maisto M; Iannotti M; Pota V; D'amora E; Sansone P; Barbarisi M
    Pain Pract; 2009; 9(2):105-14. PubMed ID: 19019049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transdermal buprenorphine for the treatment of cancer pain: results from a multicenter, observational, post-marketing study in Spain (RELIEF study).
    Camps C; Casinello J; Virizuela JA; Escobar Y; Sanchez-Magro I; Stern A
    Pain Manag; 2011 Nov; 1(6):513-22. PubMed ID: 24645762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous naloxone plus transdermal buprenorphine in cancer pain associated with intractable cholestatic pruritus.
    Marinangeli F; Guetti C; Angeletti C; Bonetti C; Paladini A; Piroli A; Varrassi G
    J Pain Symptom Manage; 2009 Oct; 38(4):e5-8. PubMed ID: 19699606
    [No Abstract]   [Full Text] [Related]  

  • 44. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.
    Mystakidou K; Parpa E; Tsilika E; Katsouda E; Kouloulias V; Kouvaris J; Georgaki S; Vlahos L
    J Pain; 2004 Mar; 5(2):119-32. PubMed ID: 15042520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain.
    Gatti A; Dauri M; Leonardis F; Longo G; Marinangeli F; Mammucari M; Sabato AF
    Clin Drug Investig; 2010; 30 Suppl 2():31-8. PubMed ID: 20670047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
    Barutell C; Camba A; González-Escalada JR; Rodríguez M;
    Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
    Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
    J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report.
    Leppert W
    Am J Hosp Palliat Care; 2014 Feb; 31(1):101-4. PubMed ID: 23349342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain.
    Naing C; Aung K; Racloz V; Yeoh PN
    J Cancer Res Clin Oncol; 2013 Dec; 139(12):1963-70. PubMed ID: 23922192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland.
    Przeklasa-Muszynska A; Dobrogowski J
    Curr Med Res Opin; 2011 Jun; 27(6):1109-17. PubMed ID: 21456888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain].
    Likar R; Griessinger N; Sadjak A; Sittl R
    Wien Med Wochenschr; 2003; 153(13-14):317-22. PubMed ID: 12924108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
    Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
    Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
    Kress HG
    Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buprenorphine in long-term control of chronic pain in cancer patients.
    Pace MC; Passavanti MB; Grella E; Mazzariello L; Maisto M; Barbarisi M; Baccari E; Sansone P; Aurilio C
    Front Biosci; 2007 Jan; 12():1291-9. PubMed ID: 17127381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].
    Wahle K; Krings D; Schwenke K
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():25-31. PubMed ID: 23678668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.
    Mercadante S; Casuccio A; Tirelli W; Giarratano A
    Support Care Cancer; 2009 Jun; 17(6):715-8. PubMed ID: 19104845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.